Post-adjuvant chemotherapy in ctDNA-positive patients with resected…
Detecting early cancer signals in blood doesn't guarantee this particular drug helps, showing the need to test what actually works for molecular residual disease.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Efficacy and safety of toripalimab in combination with cetuximab in…
Combining an immune-activating drug with a targeted antibody shows promising response rates in difficult-to-treat head and neck cancer, warranting larger studies.
Federated AI for privacy-preserving multi-institutional liver lesion detectionFederated orthogonal learning for detection of liver lesions from…
Hospitals can now collaborate on detecting liver cancer across different CT machines without sharing sensitive patient data, potentially improving care in under-resourced regions.
Novel scWGS evolutionary characterization of pediatric Burkitt lymphomaSingle-cell whole-genome sequencing reveals convergent evolution in…
Pediatric Burkitt lymphoma tumors evolve through multiple independent paths toward similar mutations, offering clues for why some patients resist treatment.
SMA gene therapy / DMT access and affordability analysisModeling the Budget Impact of Disease-Modifying Therapies in…
Three approved spinal muscular atrophy drugs cost millions per patient, with risdiplam's lifetime expense highest despite lower annual price—important for families and insurers.